Background: Multiple myeloma (MM) is a hematological malignancy characterized by the 18 clonal expansion of malignant plasma cells. Though durable remissions are possible, MM is 19 considered incurable, with relapse occurring in almost all patients. There has been limited 20 data reported on the lipid metabolism changes in plasma cells during MM progression. Here, 21
Introduction 52
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by plasma cell 53 infiltration of the bone marrow, and/or the presence of extramedullary plasmacytomas [2] . 54
With an increasing number of treatment options available, median survival for MM has 55 improved, and now approaches six years [5] . Despite advances in therapeutic strategies and 56 an increasing number of pharmacological agents to choose from, MM eventually relapses for 57 the majority of patients, hence there is a need to understand the mechanisms of relapse and 58 identify potential new therapeutic approaches. 59
The Revised International Staging System (R-ISS) for MM incorporates serum biomarkers 60 (lactate dehydrogenase, beta-2-microglobulin and albumin) and cytogenetic abnormalities of 61 known prognostic significance to predict disease behavior [4] . It is imprecise however, with 62 different patients in the same risk group exhibiting heterogeneous behavior and prognoses. 63 MM treatment strategies predominantly use regimens built around immunomodulatory drugs 64 such as thalidomide or its analogues, or proteasome inhibitors including bortezomib or 65 carfilzomib. These treatments may be followed by autologous stem cell transplantation. With 66 an increasing number of treatment options available, median survival has improved in the last 67 decade, now approaching six years [5] , but despite these advances, myeloma eventually 68 relapses for the majority of patients. 69
Perturbations in lipid metabolism are emerging as potential drivers and therapeutic targets in 70 cancer development and progression [7] . This is of particular relevance because obesity is a 71 risk factor for a number of cancer types, including multiple myeloma (MM) [1] . A pooled 72 analysis of 1.5 million participants from 20 unique prospective cohorts found a 1.2 to 1.5 fold 73 increased risk of MM mortality with increasing body mass index [3] . In addition to the 74 systemic chronic inflammation associated with obesity, increased bone marrow adiposity of 75 the MM microenvironment may directly fuel MM progression [6] . 76 77 In MM, initial lipidomic studies comparing malignant plasma cells to healthy plasma cells 78 have reported decreased levels of phosphatidylcholines [8] , and differing fatty acid 79 composition of cellular membranes [8, 9] . There are limited studies on the metabolic changes 80 that occur during MM relapse, with most studies focusing at the genomic level [10] . Using 81 Raman spectroscopy to compare between drug resistant and sensitive MM cell lines, Franco 82 et al. suggested differences in nuclear structure, as reflected by altered DNA:RNA ratio as 83 well as cholesterol and phosphatidylethanolamine content [11] . Metabolic reprogramming, 84 elevated oxidative stress response and up-regulated prostaglandin synthesis were reported by 85
Zub et al. who compared the proteome and transcriptome of melphalan sensitive and resistant 86 RPMI8226 cell lines [12] . 87 88 Advances in omics technologies herald the potential of multi-omics systems analysis, where 89 regulatory networks could be evaluated, for example, by combining proteomics and 90 transcriptomics data. One challenge of performing multi-omics analysis on clinical samples is 91 the limited patient-derived material. In this study, we investigated the feasibility of 92 conducting lipidomic and proteomic analyses from the same patient-derived plasma cell 93 sample. To validate the omics results from our pilot cohort, we compared the proteomics data 94 with a larger public transcriptomic dataset from Multiple Myeloma Research Consortium 95 reference collection, and interpreted the lipidomics data against a combined transcriptomics-96 proteomics lipid metabolism network for relapsed MM. 97
98

Materials and Methods 99
Study design and setting 100
A single-center, prospective pilot study was performed at the Princess Alexandra Hospital, 101
Brisbane, Australia. We identified patients as possible candidates (on the basis of clinical 102 features) prior to bone marrow aspiration and biopsy, and informed consent was sought prior 103 to the aspiration and biopsy procedure. Bone marrow biopsies were all performed in the 104 outpatient setting. Participant details are in Table S1 . 105
Plasma cell isolation from bone marrow 106
Plasma cells were isolated from fresh bone marrow aspirate samples using CD138 107 microbeads (Miltenyi). Purity was verified by flow cytometry (on the basis of CD38 and 108 CD138 expression) and was >80% for all samples. Purified plasma cells were stored in 109 aliquots of 10 6 cells at -80°C until analysis. 110
Lipid and protein extraction 111
Samples were selected based on laboratory confirmation of the diagnosis of myeloma with 112 >10% plasma cells in the marrow aspirate sample, and >80% of CD138 + plasma cells post-113 purification. Extraction of lipids and proteins from 10 6 isolated plasma cells was carried out 114 using a bi-phasic solvent system of cold methanol, methyl tert-butyl ether (MTBE) and water 115 [13] . Briefly, each sample was suspended in 20 µL of cold Milli-Q water and homogenized 116 with a pipette tip, followed by addition of 20 µL of a 20 µM solution of zidovudine (AZT) in 117 methanol as internal standard. Cold methanol (205 µL) was then added. The sample was 118 vortexed briefly, frozen in liquid nitrogen for 2 min, thawed, and sonicated for 10 min. The 119 freeze-thaw-sonication cycle was repeated twice. After incubating at -30 °C for 1 h, the 120 sample was extracted by 750 µL cold MTBE with shaking at 4 °C for 15 min. Phase 121 separation was induced by addition of 188 µL Milli-Q water, vortexing and centrifugation at 122 14000 g for 15 min at 4 °C. The upper phase was collected (700 µL) as the lipid-rich extract 123 fraction, and protein was recovered as the pellet. The lipid extract was evaporated to dryness 124 under vacuum and then reconstituted in 100 µL of a methanol/toluene The MS1 untargeted LC-MS data were subjected to batch Molecular Feature Extraction 147 (MFE) with Agilent Profinder (B.08.00, Agilent Technologies Inc., Santa Clara, CA, USA). 148
Data were then imported into R statistical framework for analysis. Data were first filtered to 149 retained only features that in at least 75% of samples of one or more comparison groups. 150
Remaining missing values were imputed with the minimum value. After quantile 151 normalization and log2 transformation, differential analysis was carried out using limma 152 package [15] to identify significant features (p value < 0.05, logFC > 1.5). The source nitrogen gas temperature was set to 250°C at a flow of 15 L/min. The sheath gas 171 temperature was 400°C with a flow of 12 L/min. The capillary voltage was set to 4000 V for 172 positive mode and 5000 V for negative mode and the nebulizer operated at 30 psi. Ion funnel 173 low and high pressure in positive mode were 150 and 60, and in negative mode 150 and 120 174 respectively. The autosampler was operated at 4°C and the column compartment was operated 175 at 30°C for the duration of the experiment. A solution of 95% acetonitrile was used to perform 176 the needle wash with a duration of 15 seconds. An injection volume of 8µL was used for all 177 samples. Pooled quality control (QC) samples were injected multiple times to condition the 178 HPLC column prior to analyzing the biological samples. Chromatographic separation of lipids 179 was performed using 2 different HILIC buffer systems; 25 mM ammonium formate (pH4.6) or 180 10 mM ammonium acetate (pH7.6). The acetonitrile gradient was from 50% to 95% as 181 described in Supplementary File S2. 182
Raw LC-MS data was imported into Skyline [18], where peak integration was automated but 183 manually confirmed and adjusted if required. Retention time for internal standard of each 184 lipid class was used to confirm correct peak integration of lipids belonging to the same class. 185
Peak areas were exported from Skyline for further analysis in R. Data were then normalized 186 using probabilistic quotient normalization [19] to correct for injection variations, and then 187 log2 transformed. Differential analysis was carried out using limma package identify 188 significant lipids (p value < 0.05, logFC > 1.5). 189
To perform enrichment analysis, lipid sets were generated based on class, total chain length 190 and total chain unsaturation. Lipid set enrichment analysis was performed in R using the 191 fgsea package [20] . 192
Proteomics 194
Proteins pellets were thawed on ice then centrifuged. Any excess liquid was removed and 195 samples dried under N2 for 10 min. Protein pellets were resuspended in 15 uL of buffer (70 196 mM Tris pH8, 1% sodium deoxycholate, 10 mM tris(2-carboxyethyl)phosphine and 40 mM 197 2-chloroacetamide), and sonicated in the Bioruptor (Diagenode) for 15 minutes. Protein 198 concentration was measured using DirectDetect® infrared spectrometer (Merck). A 10 µg 199 aliquot of 1 mg/mL protein extract was denatured by heating at 95°C for 5 minutes. After 200 cooling to room temperature, 0.2 µg trypsin (Promega) was added and incubated at 37C 201 overnight. Digest was stopped by acidification to 0.5 % TFA, and peptides were isolated 202 using OMIX C18 tips (Agilent). NanoLC-MS/MS was performed using a Waters 203 nanoACQUITY UPLC system interfaced to an LTQ-Orbitrap Elite hybrid mass spectrometer 204 as described in [21] . 205 Acquired data was searched using MaxQuant [22] version 1.5.8.3 against SwissProt human 206 proteome downloaded on 25/10/2017, and later exported to R for analysis. Proteins were 207 filtered according to unique peptides (≥2) and Score (>5), and then according to missing 208 values, where proteins were only kept if they were detected in at least 75% of samples of one 209 or more comparison groups. Data was then quantile normalized and remaining missing values 210 imputed using two techniques: i) proteins missing in < 25% of all samples were considered 211 missing at random, and were imputed using localized least square regression as described in 212
[23], ii) proteins missing in > 25% were imputed from a normal distribution centred at 213 minimum intensity. Log2 transformed data was analyzed using limma package to identify 214 significant proteins (p value < 0.05, logFC > 1.5). Pathway enrichment analysis was carried 215 Following clinical diagnosis, plasma cell isolation and quality control, a total of 7 participant 238 samples were available for inclusion (Table S1 ). For each participant, 1×10 6 plasma cells 239 were extracted for proteomics and lipidomics analyses. Lipidomics was performed using both 240 untargeted and targeted approaches. Two comparisons were conducted based on clinical 241 information, with the caveat that the sample sizes were small in this study. Firstly, high risk 242 MM (n=3) were compared to low risk MM (n=4) according to R-ISS staging. Secondly, 243 relapsed/refractory MM (RRMM, n=2) versus newly diagnosed MM (NDMM, n=7). 
Targeted lipidomics profiling of plasma cells 268
The targeted lipidomics method included 313 lipids, from which 219 lipids were retained 269 after manual inspection and filtering through Skyline (Supplementary File 4) . Differential 270 analysis confirmed untargeted profiling results with several PCs diminished in both high risk 271
and RRMM (Table 3) . To investigate if the observed differences are specific to particular 272 lipid class, we performed Lipid set enrichment analysis (Figure 1, Supplementary File 4) , 273 which revealed significant down-regulation trend in PCs in both high risk and RRMM. 274
Ceramides and lyso-PEs were significantly enriched for upregulation in high risk patients, 275 while down-regulated in RRMM. Elevated levels of phosphatidylethanolamines (PEs), 276 sphingomyelins and sphingosines resulted in significant enrichment of these classes in 277 
RRMM. 278
Untargeted proteomics of plasma cells 286
In the untargeted proteomic analysis, 4169 proteins were identified, of which 2569 were 287 subjected to differential analysis after filtering. Difference between risk groups was limited to 288 28 significant proteins, while RRMM vs NDMM comparison reported 182 differential 289 proteins, the majority of which are down-regulated (Supplementary File 5) . Enrichment 290 analysis using Reactome pathways identified ~ 150 significant pathways in RRMM 291 (Supplementary File 6) . In contrast, risk groups had only ~25 enriched pathways, mostly 292 related to extracellular matrix. 293 294
Comparison of RRMM proteomics dataset with gene expression data 295
In both lipidomics and proteomics measurements, the differences between RRMM and 296 NDMM were larger than those observed between risk groups. We followed up on these 297 observations in RRMM by integrative analysis with the publicly available MMRC reference 298 collection which contains gene expression profiles for plasma cells from a total of 222 299 patients, with 107 being NDMM (termed untreated) and 115 RRMM (termed treated). 300
Mapping microarray probes to their corresponding UniProt IDs obtained expression levels for 301 ~ 17,000 genes. Differential expression analysis followed by pathway enrichment identified 302 430 significant pathways (Supplementary File 6) . 303
304
There was significant overlap between the proteomics results from our cohort and the 305 independent transcriptomics results at the pathway level but not at the gene level 306 (hypergeometric test, Figure 2) . Out of 6900 significantly expressed genes, 62 genes were 307 also found significant at the protein level, only 20 of which were regulated in the same 308 direction (p = 0.99) (Supplementary File 5) . Interestingly, out of the 430 significantly 309 enriched pathways in the transcriptomics dataset, 76 pathways were also enriched at the 310 protein level, 67 of which in the same direction (p < 1e-16). Overlapped pathways included 311 TCR, NF-kß signalling and protein synthesis pathways (Supplementary File 6) . 312
313
Network analysis 314
Next, we focused on the lipid related pathways in RRMM. Reactome pathway group 315 "Metabolism of lipids" was converted into a single connected network using NetPathMiner R 316 package. Following the package instructions, small ubiquitous compounds, such as water and 317 co-factors, were removed to prevent over-connectivity of the network, resulting in a network 318 with 1130 nodes and 1571 edges. Metabolite nodes were then removed to obtain a reaction 319 network, subsequently weighting the edges using transcriptomics datasets (see Methods). Top 320 correlated paths showed strong association with their corresponding conditions. This was 321 demonstrated by the ability of pathClassifier function to correctly predict path condition. 322
Receiver Operating Characteristic (ROC) curve showed area under the curve (AUC) of 0.995, 323
indicating high sensitivity and specificity of the path classifier (Figure ) . 324
Subnetworks constructed from correlated paths resulted in substantially smaller networks. In 325 RRMM, a subnetwork of 101 nodes and 125 edges was obtained, with paths related to PCs, 326 ceramides, cardiolipin metabolism, production of leukotrienes, exotoxins from arachidonic 327 acid (AA), and production of dihydroxycholestanoic acid from cholesterol (Figure 4, red  328 edges). On the other hand, the subnetwork correlated amongst NDMM consisted of 87 nodes 329 and 96 edges, and incorporated FA and PE metabolism, production of prostaglandins and 330 thromboxanes from AA, and production of phosphoserine from cholesterol. Subnetworks 331 from both conditions showed a small overlap, with only 32 nodes and 23 edges (Figure 4 , 332 grey edges). 333
Exploring the proteomics data in the context of correlated subnetwork for RRMM revealed a 334 low detection rate (Figure 5) . Notably, PLBD1, a phospholipase B implicated in sn1 and sn2 335 hydrolysis PCs, was up-regulated in RRMM proteomics and transcriptomics. This up-336 regulation of PLBD1, along with the correlation of PC metabolic subnetwork in RRMM, 337 propose a possible explanation for the reduced levels of PCs observed in lipidomics data. 338
Discussion 339
This study confirmed the feasibility of conducting concurrent lipidomics and proteomics 340 profiling of freshly isolated plasma cells from patients with MM. We observed more 341 lipidomic and proteomic differences between RRMM and NDMM, than between high and 342 low risk MM based on the current R-ISS staging system. As an initial cross-validation, the 343 proteomics data from our small pilot cohort was compared to a larger transcriptomics dataset 344 for RRMM versus NDMM cases. This comparison revealed limited overlap at the 345 transcript/gene level, likely due to the lower proteomics depth compared to transcriptomics. 346 However, significant correlation was observed in the differential pathways at the transcript 347 and proteome level, indicating agreement of our pilot cohort data with the larger 348 transcriptome data. Together, these results confirm the feasibility of concurrent lipidomics 349 and proteomics analyses from a single aliquot of one million plasma cells prepared from 350 freshly collected bone marrow. Furthermore, although the proteomic coverage of lipid metabolic enzymes was overall very 362 limited, we found phospholipase B-like 1 gene product PLBD1 to be elevated in RRMM. The 363 major cellular phospholipases that participate in signal transduction are PLA, PLC and PLD 364 [28] . PLBD1 was recent identified from neutrophils as a phospholipase which removes fatty 365 acids from either sn-1 or sn-2 positions [30] . Coupled with observed high level of transcripts 366 in the arachidonic pathway, it is tempting to suggest that elevated PLBD1 levels contributes 367 to MM progression and relapse by increasing arachidonic acids levels. Future studies in 368 larger cohorts should examine this pathway. 369
370
We acknowledge that the small patient numbers in our study limit the broader applicability of 371 the work, but in our small dataset, plasma cells from patients with RRMM appear to have a 372 different lipidomic and proteomic profile when we compare with samples from NDMM. This 373 is potentially clinically relevant, as patients who have relapsed disease experience poorer 374 outcomes, with shorter periods of disease control than patients receiving front-line therapy at 375 first diagnosis. The altered lipidomic and proteomic profile observed may reflect the clonal 376 evolution that occurs in the malignant cells over time following serial chemotherapeutic 377 challenges. To this end, it is interesting to note that PC is an important lipid in maintaining 378 endoplasmic reticulum (ER) function, and that ER stress response pathways is implicated in 379 the development of resistance to proteasome inhibitors in MM [31] . Further studies, with 380 larger groups of patients will be beneficial in establishing the relationship between clonal 381 evolution, subsequent lipidomic and proteomic changes. These results may enable 382 personalized therapy selection, thereby improving patient outcomes. 383
384
In summary, we report the feasible concurrent lipidomic and proteomic analyses of purified 385 plasma cells collected from a small cohort of multiple myeloma patients. As the goal was to 386 determine the methodological feasibility and develop a suitable workflow, interpretation of 387 the biological data from this study is limited by the small cohort size and possible 388 confounders which were not considered. Nonetheless, in alignment with previous reports of 389 reduced levels of PCs in MM (compared with healthy plasma cells), we observed reduced 390 levels of several PCs in high risk MM and in RRMM. Furthermore, independent 391 transcriptome data from a larger cohort corroborates altered PC metabolism in RRMM, and 392 further suggest altered arachidonic acid and eicosanoid metabolism. We believe these 393 preliminary observations warrants further exploration in a larger cohort, as these approaches 394 are 
